Sphera Funds Management Ltd. Altimmune, Inc. Transaction History

Sphera Funds Management Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $690,000 - $1.19 Million	200,000 Added 66.67%	500,000 $1.77 Million
Q1 2023 May 15, 2023	SELL	$4.19 - $16.83 $336,448 - $1.35 Million	-80,298 Reduced 21.11%	300,000 $1.27 Million
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $1.92 Million - $3.62 Million	-220,000 Reduced 36.65%	380,298 $6.26 Million
Q3 2022 Nov 14, 2022	SELL	$10.67 - $22.41 $8.46 Million - $17.8 Million	-792,586 Reduced 56.9%	600,298 $7.67 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $338,568 - $1.01 Million	85,931 Added 6.57%	1,392,884 $16.3 Million
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $370,000 - $592,628	62,712 Added 5.04%	1,306,953 $7.96 Million
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $1.35 Million - $1.94 Million	155,387 Added 14.27%	1,244,241 $11.4 Million
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $3.42 Million - $6.82 Million	405,459 Added 59.33%	1,088,854 $12.3 Million
Q2 2021 Aug 17, 2021	BUY	$9.85 - $16.46 $6.73 Million - $11.2 Million	683,395 New	683,395 $6.73 Million
Q4 2020 Feb 16, 2021	SELL	$7.84 - $14.22 $1.91 Million - $3.46 Million	-243,000 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$9.93 - $33.26 $2.41 Million - $8.08 Million	243,000 New	243,000 $3.21 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $404M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Sphera Funds Management Ltd., based on Form 13F filings with the SEC.

Stay updated on Sphera Funds Management Ltd. with notifications on news.